Publications from the Centre for Immuno-Oncology
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
Crescioli S. et al, (2023), Nature Communications, 14
Enriched circulating and tumor-resident TGF-β + regulatory B cells in patients with melanoma promote FOXP3 + Tregs
Harris RJ. et al, (2022), OncoImmunology, 11
B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge
Egbuniwe IU. et al, (2022), Journal of Investigative Dermatology, 142, 726 - 731.e4
Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients
Karagiannis P. et al, (2022), Clinical and Experimental Immunology, 207, 84 - 94
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
Harris RJ. et al, (2021), Cancer Research, 81, 4290 - 4304
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
Roulstone V. et al, (2021), Journal for ImmunoTherapy of Cancer, 9, e002673 - e002673
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Willsmore ZN. et al, (2021), European Journal of Immunology, 51, 544 - 556
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Willsmore ZN. et al, (2021), Frontiers in Immunology, 11
Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma
Nakamura M. et al, (2019), OncoImmunology, 8, e1593811 - e1593811
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Khair DO. et al, (2019), Frontiers in Immunology, 10